Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 + CD22 CAR T cells
- Development stage
- Unknown
- Lead developer
- Shanghai Pharmaceuticals
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19 + CD22 CAR T cells (specifically the B019 construct) is an investigational bicistronic chimeric antigen receptor (CAR) T-cell therapy developed by Shanghai Children's Medical Center and Shanghai Jiao Tong University School of Medicine. This cell and gene therapy utilizes a single CAR construct to simultaneously target two B-cell surface antigens, CD19 and CD22, aiming to mitigate immune escape and antigen loss—common resistance mechanisms in single-target CAR T therapies. It is primarily being evaluated for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) in pediatric and adolescent patients. Clinical data from large cohorts have demonstrated high complete response rates and favorable event-free survival.
- Other names
- CD19/CD22 bicistronic CAR-T cellsCD19+CD22 CAR T cells
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CD19 + CD22 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 + CD22 CAR T cells.